Author Names in order: Laura C. Coates, Lars Erik Kristensen, Alexis Ogdie, William Tillett, Barbara Ink, Nadine Goldammer, Rajan Bajracharya, Jason Coarse, Ana-Maria Orbai
Presenting Author (at EULAR): Laura C. Coates
Abstract or description:Abstract/Description Text: We assessed the efficacy of bimekizumab using Minimal Disease Activity (MDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) up to 2 years in patients with active psoriatic arthritis (PsA) who were bDMARD-naïve or had prior inadequate response/intolerance to TNFi, in the phase 3 trials BE OPTIMAL and BE COMPLETE. Bimekizumab-treated patients with PsA achieved sustained MDA responses and DAPSA improvements from baseline up to 2 years. Improvements were observed across all patient-reported and most clinical components of MDA, with robust improvements observed in joint and skin outcomes. Bimekizumab was well tolerated; no new safety signals were observed.
Abstract Source: EULAR 2024, 12-15 June, Vienna, Austria
These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.
Author Names in order: Laura C. Coates, Lars Erik Kristensen, Alexis Ogdie, William Tillett, Barbara Ink, Nadine Goldammer, Rajan Bajracharya, Jason Coarse, Ana-Maria Orbai
Presenting Author (at EULAR): Laura C. Coates
Abstract or description:Abstract/Description Text: We assessed the efficacy of bimekizumab using Minimal Disease Activity (MDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) up to 2 years in patients with active psoriatic arthritis (PsA) who were bDMARD-naïve or had prior inadequate response/intolerance to TNFi, in the phase 3 trials BE OPTIMAL and BE COMPLETE. Bimekizumab-treated patients with PsA achieved sustained MDA responses and DAPSA improvements from baseline up to 2 years. Improvements were observed across all patient-reported and most clinical components of MDA, with robust improvements observed in joint and skin outcomes. Bimekizumab was well tolerated; no new safety signals were observed.
Abstract Source: EULAR 2024, 12-15 June, Vienna, Austria
These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.
